Table 5. Literature review of cytoreductive surgery and perioperative intraperitoneal chemotherapy for malignant peritoneal mesothelioma (16).
Treatment center | Number of patients | Residual disease status | HIPEC technique | PIC agents | HIPEC duration (min) | HIPEC Temp (°C) | Mortality (%) | 5-year OS (%) | Median survival (months) | Grade III/IV morbidity (%) |
---|---|---|---|---|---|---|---|---|---|---|
Multicenter, 2011 (60) | 294 | 47% <2.5 mm | Variable | Variable | Variable | Variable | – | 52 | 67 | – |
Milan, Italy, 2010 (61) | 83 | 80% <2.5 mm | Closed | Cisplatin, MMC | 90 | 42.5 | 2.4 | 50 | 44 | 28 |
Multicenter, 2009 (62) | 401 | 46% <2.5 mm | Variable | Variable | Variable | Variable | 2 | 47 | 53 | 31 |
New York, NY, 2008 (63) | 27 | 1st surgery: 44% <5 mm; 2nd surgery: 48% <5 mm | Open | Cisplatin, doxorubicin, γINF, MMC | 60 | 41 | 0 | 67 (3-year) | 70 | 30 |
Washington, DC, 2007 (64) | 62 | 37% <2.5 mm | Open | Cisplatin, doxorubicin. EPIC: paclitaxel | 90 | 41.5 | 3 | 50 | 79 | 41 |
Lyon, France, 2006 (65) | 15 | 73% <2.5 mm | Closed | Cisplatin, MMC | 90 | 42 | 0 | 29 | 36 | 40 |
Milan, Italy, 2006 (66) | 49 | 82% <2.5 mm | Closed | Cisplatin, doxorubicin, MMC | 90 | 42.5 | 0 | 57 | Not reached | 27 |
NCI, Bethesda, MD, 2003 (67) | 49 | 88% <1 cm; 33% <5 mm | Open | Cisplatin. EPIC: paclitaxel | 90 | 41 | 0 | 59 | 92 | 25 |
Wake Forest, NC, 2001 (1) | 12 | 60% <2.5 cm | Closed | MMC | 120 | 42.5 | 8 | 33 | 34 | – |
Adapted from (16). HIPEC, hyperthermic intraperitoneal chemotherapy; MMC, mitomycin C; EPIC, early post-operative intraperitoneal chemotherapy.